Ozempic and Stomach Paralysis (Gastroparesis): What You Need to

One of the more alarming side effects linked to GLP-1 medications like Ozempic and Wegovy is gastroparesis — a condition where the stomach is partially paralyzed and empties too slowly. Here’s what the evidence actually shows, who’s at risk, and what to do if you’re concerned.

What Is Gastroparesis?

Gastroparesis literally means “stomach paralysis.” The stomach normally contracts rhythmically to push food into the small intestine. In gastroparesis, those contractions are weakened or absent, causing food to sit in the stomach for much longer than normal. Symptoms include:

• Nausea and vomiting (sometimes hours after eating)
• Feeling full after just a few bites
• Bloating and abdominal pain
• Acid reflux worsening
• Unpredictable blood sugar levels
• Unintentional weight loss (severe cases)

How Do GLP-1 Medications Affect Stomach Emptying?

This is the crux of the issue. GLP-1 receptor agonists like semaglutide intentionally slow gastric emptying — that’s actually part of how they work to suppress appetite and reduce blood sugar spikes after meals. This deliberate slowing is normal, expected, and generally modest in most patients.

The concern is whether this mechanism can trigger true clinical gastroparesis in some individuals, or severely worsen pre-existing gastroparesis.

What Does the Research Show?

In 2023, a large pharmacovigilance study published in JAMA found that GLP-1 receptor agonists were associated with a significantly higher risk of gastroparesis diagnosis compared to bupropion-naltrexone (another weight loss drug). Specifically:

Condition	GLP-1 Agonists vs Control	Notes
Gastroparesis	3.67x higher risk	Based on diagnosis codes; absolute risk still low
Pancreatitis	9.09x higher risk	Rare in absolute terms
Bowel obstruction	4.22x higher risk	Largely in patients with prior history

However, context matters. The absolute number of gastroparesis cases was still small, and the study had limitations (reliance on insurance claims data, inability to control for all confounders). Pre-existing diabetes itself is a major cause of gastroparesis, complicating cause-and-effect conclusions.

The FDA’s Position

The FDA updated prescribing information for GLP-1 medications to note that ileus (intestinal obstruction) and gastroparesis have been reported. As of 2024–2025, gastroparesis is listed as a potential adverse event in the prescribing information but is not a contraindication for most patients.

Risk Factors for Severe Gastric Slowing on GLP-1s

Risk Factor	Why It Matters
Pre-existing gastroparesis	GLP-1s can severely worsen already-impaired motility
Long-standing type 2 diabetes	Diabetic autonomic neuropathy already impairs stomach nerves
Prior GI surgery	Altered anatomy may increase risk
High doses quickly	Rapid dose escalation increases GI side effect burden
Opioid use	Opioids also slow motility — combination effect

Warning Signs to Watch For

Distinguish normal GLP-1 GI side effects (mild nausea, some fullness) from potential gastroparesis warning signs:

Normal GLP-1 Side Effect	Possible Gastroparesis Warning Sign
Mild nausea, especially early	Vomiting undigested food hours after eating
Feeling full quickly	Severe, persistent fullness even after small meals
Occasional bloating	Constant abdominal distension/pain
Slight acid reflux	Significant worsening of GERD symptoms
Soft stools / constipation	Unable to keep any food down

What to Do If You’re Concerned

Don’t stop medication abruptly without talking to your doctor. If you’re experiencing severe symptoms, contact your prescriber promptly. Evaluation may include a gastric emptying study (a nuclear medicine scan that measures how fast food moves through your stomach). If gastroparesis is confirmed, your doctor will likely reduce your GLP-1 dose or discontinue the medication until motility normalizes.

Important Note for Surgery Patients

Anesthesiologists have raised concerns about GLP-1 medications before surgery. Because these drugs slow gastric emptying, the standard “nothing by mouth after midnight” rule may not be sufficient to ensure an empty stomach — which poses aspiration risk during anesthesia. The American Society of Anesthesiologists recommends holding GLP-1 medications before elective procedures. Discuss timing with both your prescriber and anesthesiologist before any surgery.

The Bottom Line

True gastroparesis from GLP-1 medications is rare but real. The mechanism is plausible (these drugs intentionally slow stomach emptying), and reports in the literature have increased with the massive expansion of GLP-1 prescribing. Most people experience only manageable GI slowing that contributes to satiety. But patients with pre-existing gastroparesis, long-standing diabetes, or severe GI symptoms on GLP-1s should discuss the risk carefully with their prescriber.

Frequently Asked Questions

Does Ozempic cause permanent stomach paralysis?
In most cases, no. GI effects from GLP-1 medications typically resolve after stopping the drug. However, in rare cases or in those with underlying motility disorders, effects may be prolonged. There is no strong evidence that Ozempic causes permanent gastroparesis in patients without pre-existing risk factors.

How common is gastroparesis on Ozempic?
Relatively rare. Clinical trials did not flag gastroparesis as a common adverse event. The 2023 pharmacovigilance study found an elevated relative risk, but absolute rates remain low. The majority of GLP-1 users experience only temporary, mild GI effects.

Should I stop Ozempic before surgery?
Yes, in most cases. Current guidance recommends holding weekly GLP-1 injections for at least 1 week before elective surgery (some guidelines suggest longer for higher-dose weekly drugs). Always discuss the specific timeline with your surgical team.

Can I take Ozempic if I already have gastroparesis?
GLP-1 medications are generally contraindicated in patients with known gastroparesis, as they can significantly worsen the condition. Discuss alternatives with your prescriber.